drugset
drugset / Trial / NCT03939715

Surgical Intervention With DermaPure vs Native Tissue in Pelvic Organ Prolapse

NCT03939715 ↗

Phase 4 Unknown 50 enrolled Colorado Pelvic Floor Consultants Tissue Regenix Ltd · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparing FDA-approved DermaPure with patient's own native tissue surgically for diagnosis of pelvic organ prolapse.

Timeline

Start
2020-04-05
Primary completion
2022-05-05
Completion
2022-05-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator DermaPure® Other / unclassified — —

Indications

pelvic organ prolapse